Not all providers are equally comfortable managing this combination
So Harlan Krumholz: Talk to you soon, Howie. Howard Forman: Thanks very much, Harlan
Furthermore, Figure 4Bs analysis of struggle time percentages reinforce these findings
Function of the oxidative burst in hypersensitive disease resistance
Given the substantial resource demands of drug development, large sample sizes, extended trial durations, and the financial and physiological burden of certain treatments (e.g., monoclonal antibodies targeting A), it is ethically and scientifically imperative to identify patients for whom benefit is plausible and to avoid unnecessary exposure of those unlikely to respond
Hurtado, I., Robles, C., Peir, S., Garca-Sempere, A